|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: USP33 |
Gene summary for USP33 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | USP33 | Gene ID | 23032 |
| Gene name | ubiquitin specific peptidase 33 | |
| Gene Alias | VDU1 | |
| Cytomap | 1p31.1 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8TEY7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23032 | USP33 | CA_HPV_1 | Human | Cervix | CC | 3.31e-02 | 3.62e-02 | 0.0264 |
| 23032 | USP33 | CCI_1 | Human | Cervix | CC | 1.47e-02 | 7.50e-01 | 0.528 |
| 23032 | USP33 | CCI_2 | Human | Cervix | CC | 2.04e-08 | 1.09e+00 | 0.5249 |
| 23032 | USP33 | CCI_3 | Human | Cervix | CC | 1.18e-06 | 8.17e-01 | 0.516 |
| 23032 | USP33 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.04e-13 | -4.60e-01 | 0.0155 |
| 23032 | USP33 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.16e-04 | -3.40e-01 | 0.096 |
| 23032 | USP33 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.63e-04 | -2.91e-01 | 0.0674 |
| 23032 | USP33 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.70e-05 | -4.78e-01 | 0.0588 |
| 23032 | USP33 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 4.50e-02 | -4.38e-01 | 0.2585 |
| 23032 | USP33 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.08e-15 | -5.34e-01 | 0.3005 |
| 23032 | USP33 | A001-C-207 | Human | Colorectum | FAP | 4.43e-03 | -1.68e-01 | 0.1278 |
| 23032 | USP33 | A015-C-203 | Human | Colorectum | FAP | 5.06e-21 | -3.20e-01 | -0.1294 |
| 23032 | USP33 | A015-C-204 | Human | Colorectum | FAP | 1.95e-05 | -2.25e-01 | -0.0228 |
| 23032 | USP33 | A014-C-040 | Human | Colorectum | FAP | 4.53e-04 | -3.22e-01 | -0.1184 |
| 23032 | USP33 | A002-C-201 | Human | Colorectum | FAP | 5.14e-14 | -1.99e-01 | 0.0324 |
| 23032 | USP33 | A002-C-203 | Human | Colorectum | FAP | 1.16e-04 | -2.38e-01 | 0.2786 |
| 23032 | USP33 | A001-C-119 | Human | Colorectum | FAP | 3.58e-03 | -3.05e-02 | -0.1557 |
| 23032 | USP33 | A001-C-108 | Human | Colorectum | FAP | 1.04e-09 | -6.55e-02 | -0.0272 |
| 23032 | USP33 | A002-C-205 | Human | Colorectum | FAP | 2.03e-19 | -2.46e-01 | -0.1236 |
| 23032 | USP33 | A015-C-005 | Human | Colorectum | FAP | 3.22e-05 | -2.58e-01 | -0.0336 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010506 | Colorectum | AD | regulation of autophagy | 111/3918 | 317/18723 | 3.57e-09 | 2.35e-07 | 111 |
| GO:0050821 | Colorectum | AD | protein stabilization | 73/3918 | 191/18723 | 3.02e-08 | 1.64e-06 | 73 |
| GO:0051099 | Colorectum | AD | positive regulation of binding | 66/3918 | 173/18723 | 1.47e-07 | 6.64e-06 | 66 |
| GO:0043393 | Colorectum | AD | regulation of protein binding | 68/3918 | 196/18723 | 5.17e-06 | 1.34e-04 | 68 |
| GO:0031667 | Colorectum | AD | response to nutrient levels | 138/3918 | 474/18723 | 1.22e-05 | 2.68e-04 | 138 |
| GO:0007409 | Colorectum | AD | axonogenesis | 122/3918 | 418/18723 | 3.36e-05 | 6.15e-04 | 122 |
| GO:0061564 | Colorectum | AD | axon development | 132/3918 | 467/18723 | 8.40e-05 | 1.31e-03 | 132 |
| GO:0032092 | Colorectum | AD | positive regulation of protein binding | 33/3918 | 85/18723 | 1.22e-04 | 1.78e-03 | 33 |
| GO:0042594 | Colorectum | AD | response to starvation | 63/3918 | 197/18723 | 1.77e-04 | 2.38e-03 | 63 |
| GO:0071496 | Colorectum | AD | cellular response to external stimulus | 94/3918 | 320/18723 | 1.98e-04 | 2.64e-03 | 94 |
| GO:0009267 | Colorectum | AD | cellular response to starvation | 51/3918 | 156/18723 | 3.90e-04 | 4.44e-03 | 51 |
| GO:0051100 | Colorectum | AD | negative regulation of binding | 50/3918 | 162/18723 | 1.84e-03 | 1.51e-02 | 50 |
| GO:0031668 | Colorectum | AD | cellular response to extracellular stimulus | 71/3918 | 246/18723 | 1.86e-03 | 1.52e-02 | 71 |
| GO:0031669 | Colorectum | AD | cellular response to nutrient levels | 63/3918 | 215/18723 | 2.19e-03 | 1.73e-02 | 63 |
| GO:0007411 | Colorectum | AD | axon guidance | 64/3918 | 227/18723 | 5.41e-03 | 3.55e-02 | 64 |
| GO:0097485 | Colorectum | AD | neuron projection guidance | 64/3918 | 228/18723 | 6.02e-03 | 3.78e-02 | 64 |
| GO:0032091 | Colorectum | AD | negative regulation of protein binding | 30/3918 | 94/18723 | 8.26e-03 | 4.85e-02 | 30 |
| GO:00316472 | Colorectum | MSS | regulation of protein stability | 103/3467 | 298/18723 | 2.52e-11 | 3.49e-09 | 103 |
| GO:00510982 | Colorectum | MSS | regulation of binding | 113/3467 | 363/18723 | 3.55e-09 | 2.41e-07 | 113 |
| GO:00508212 | Colorectum | MSS | protein stabilization | 68/3467 | 191/18723 | 1.53e-08 | 8.81e-07 | 68 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| USP33 | SNV | Missense_Mutation | c.1236C>G | p.Ile412Met | p.I412M | Q8TEY7 | protein_coding | tolerated(0.23) | benign(0.015) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| USP33 | SNV | Missense_Mutation | novel | c.1978C>A | p.Leu660Met | p.L660M | Q8TEY7 | protein_coding | tolerated(0.07) | possibly_damaging(0.688) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| USP33 | SNV | Missense_Mutation | c.1728N>G | p.Phe576Leu | p.F576L | Q8TEY7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| USP33 | SNV | Missense_Mutation | c.318C>A | p.Asn106Lys | p.N106K | Q8TEY7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR | |
| USP33 | SNV | Missense_Mutation | novel | c.61A>C | p.Ser21Arg | p.S21R | Q8TEY7 | protein_coding | deleterious_low_confidence(0.05) | benign(0.076) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| USP33 | SNV | Missense_Mutation | c.1031N>T | p.Asn344Ile | p.N344I | Q8TEY7 | protein_coding | tolerated(0.2) | benign(0.102) | TCGA-E2-A150-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| USP33 | insertion | Nonsense_Mutation | novel | c.2806_2807insCAGATCCATAGTATCCTTTGTAGTGTTGTAAAT | p.Glu936delinsAlaAspProTerTyrProLeuTerCysCysLysTer | p.E936delinsADP*YPL*CCK* | Q8TEY7 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| USP33 | SNV | Missense_Mutation | novel | c.2081T>C | p.Val694Ala | p.V694A | Q8TEY7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| USP33 | SNV | Missense_Mutation | c.968N>T | p.Ser323Phe | p.S323F | Q8TEY7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| USP33 | SNV | Missense_Mutation | c.968N>T | p.Ser323Phe | p.S323F | Q8TEY7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |